MedTrace Logo

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-03-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.

Conditions

  • Knee Arthroplasty, Total

Interventions

DRUG

Losartan

12.5 mg oral Losartan taken for 28 days total (4 week postoperative).

DRUG

Placebo - Losartan

Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).

Sponsors & Collaborators

  • Steadman Philippon Research Institute

    lead OTHER

Principal Investigators

  • Johnny Huard, PhD · Steadman Philippon Research Institute

  • Scott Tashman, PhD · Steadman Philippon Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108063 on ClinicalTrials.gov